What Duratocin Treats: Main Uses and Benefits

Duratocin is used to help manage the risk of postpartum hemorrhage (PPH), which is an acute condition that may follow childbirth. The medication is used in situations involving certain distressing symptoms linked to organ-specific functional stress, specifically insufficient muscle tone of the uterus. It may be applied when supportive symptom management is appropriate, particularly during the time period when the risk of bleeding is heightened.

This drug is relevant across conditions presenting with acute episodes of severe bleeding. The medication provides support that helps ease the overall symptom burden by encouraging uterine function.

Clinical Focus and Patient Benefit

Duratocin is commonly used in settings marked by temporary physiological imbalance, specifically where the uterus needs additional support to contract firmly and steadily. It is applied across domains where additional symptomatic support is needed to address the need for adequate muscle function. The use of this medicine contributes to easing the overall symptom load during periods of heightened symptoms and supports general well-being during symptomatic phases.

Quick Fact: Supportive Management for Acute Physiological Stress

Regulatory References

1. Therapeutic Goods Administration (TGA) of Australia

Who Can and Cannot Use Duratocin?

The eligibility for Duratocin (Carbetocin) is strictly defined by regulatory guidelines, focusing on the patient's delivery status, age, and pre-existing health conditions. Use is authorized only after the delivery of the infant.

---

Eligibility Rules Based on Regulatory Status

Classification	Population or Condition
Populations for whom use is allowed	Women after delivery (postpartum)
Populations for whom use is contraindicated	Pregnancy and labor before delivery; Hypersensitivity to carbetocin or oxytocin; Serious cardiovascular disorders; Renal or hepatic disease; Epilepsy
Populations for whom use is not recommended	Adolescents (<18 years); Geriatrics (>65 years)

---

Eligibility-Related Restrictions

• Pregnancy Status: The medicine is contraindicated during pregnancy, including for labor induction or augmentation.
• Organ Function: Use is contraindicated in patients with renal or hepatic disorders because the drug's safety in these populations has not been investigated.
• Special Caution: Official labels recommend use with special caution in patients with eclampsia, pre-eclampsia, known long QT syndrome, severe cardiovascular disease (especially coronary artery disease), migraine, or asthma.
• Lactation Status: Breastfeeding does not need to be restricted following a single administration, as the amount transferred into breast milk is not expected to be clinically significant.

The official interaction profile for Duratocin (Carbetocin) is structured based on its classification as an oxytocin analogue, as formal drug interaction studies have not been conducted. The profile relies on documented pharmacodynamic interactions, which involve additive or synergistic effects on the body's systems.

Pharmacodynamic Interactions Co-administration with other uterotonic agents, including oxytocin, carries a risk of cumulative effects due to additive activity on the uterus. Similarly, simultaneous use with Prostaglandins is generally not recommended, as they are known to potentiate uterotonic effects, mandating close monitoring if unavoidable.

A risk of cardiovascular potentiation is noted with specific substances. The drug may intensify the blood pressure-enhancing effect of vasoconstrictor agents, an observation documented with oxytocin that cannot be ruled out. Caution regarding the timing of administration is warranted, as severe hypertension was reported when oxytocin was given a few hours following prophylactic vasoconstrictor use. Additionally, inhalation anaesthetics (such as Halothane) may both potentiate hypotension and reduce the desired uterotonic effect.

Other Interaction Considerations No specific interactions involving metabolic pathways like CYP enzymes or drug transporters have been established or formally documented. Similarly, official prescribing information notes the absence of documented interactions with food, alcohol, or herbal products. Special caution is required for patients with long-QT syndrome due to the potential for an additive effect on cardiac repolarization, based on observations with the analogue oxytocin.

How Duratocin Works

Duratocin (carbetocin) is a synthetic analog of oxytocin that functions as a selective agonist for oxytocin receptors (OTRs), which are G-protein coupled receptors predominantly expressed in the myometrium (uterine muscle). The drug binds to these receptors with high affinity.

The binding of Duratocin to the OTR initiates a signal transduction cascade by activating the heterotrimeric Gq protein. This activation triggers the hydrolysis of phosphatidylinositol 4,5-bisphosphate ( PIP2) via phospholipase C, yielding the secondary messengers inositol triphosphate ( IP3) and diacylglycerol ( DAG). IP3 subsequently acts on receptors in the sarcoplasmic reticulum, triggering the rapid release of stored calcium ions ( Ca^2+) into the myocyte cytoplasm.

This increased cytosolic Ca^2+ binds to calmodulin, forming a complex that activates the enzyme myosin light-chain kinase (MLCK). MLCK then phosphorylates the myosin light chains, promoting the interaction between the actin and myosin filaments. This entire cascade ultimately results in the strong, rhythmic, and sustained contraction of the uterine smooth muscle. Duratocin's prolonged half-life ensures sustained interaction with the OTR.

How Duratocin is Used: Official Administration Guidelines

Duratocin (carbetocin) is used according to standardized clinical guidelines, dictating its administration as a single, preventative dose immediately following childbirth. The instructions below describe how the medicine is used, ensuring proper delivery in the clinical setting.

---

Administration Details

Administration Component	Official Instruction
Route of Administration	Intravenous (IV) Injection or Intramuscular (IM) Injection
Standard Dose	A single administration of 100 micrograms (1 mL)
Timing	Administer as soon as possible after delivery of the infant
Administration Setting	Must be given under adequate medical supervision in a hospital setting

---

Procedural and Dosing Rules

The use of Duratocin is limited to a one-time event and is not part of a repeated or maintenance regimen:

• Single Use Only: The 100 microgram dose is administered only once. Administration must not be repeated. If uterine tone is not adequate, alternative uterotonic agents must be considered.
• IV Administration Speed: When administered intravenously, the dose must be injected slowly over 1 minute.
• Crucial Timing Restriction: The drug is not to be administered prior to the delivery of the infant.
• Specific Populations: The same 100 microgram dose may be used in adolescents (from 15 years) under adequate supervision.

These instructions define the standardized approach to the medicine's use as established in clinical documentation.

Research evidence / Overview of studies for Duratocin

---

Evidence for Preventing Severe Bleeding Following Cesarean Delivery

The research examined the use of the medicine in women undergoing Cesarean Delivery (CD) compared to the standard of care. These studies explored how the uterus contracted after delivery and tracked specific outcomes, such as estimated blood loss, changes in maternal hemoglobin, and the frequency of severe bleeding events. Findings describe patterns observed in the studies regarding the reported need for administering additional uterotonic medications. Studies reported measurements related to blood management that were consistent across several high-quality reviews.

---

Evidence for Preventing Severe Bleeding Following Vaginal Delivery

Research examined the use of the medicine in large-scale Randomized Controlled Trials (RCTs) following vaginal delivery. Studies monitored outcomes for the frequency of defined bleeding events and the requirement for subsequent rescue medications. Studies monitored patterns related to the proportion of women requiring subsequent intervention. However, for the severity of bleeding measured as (ge 1000 mL), findings were mixed or inconsistent across the studies that examined this endpoint. The overall evidence base has been assigned a Moderate certainty level.

---

Long-Term Research and Follow-up Duration

The vast majority of major trials were relevant in research assessing short-term observations of uterine function immediately after delivery. Long-term effects are not fully established because follow-up durations were limited, generally only covering the first 24 hours after birth. Therefore, there is limited information for long-term outcomes regarding maternal health and functional well-being.

---

What Is Still Uncertain About Duratocin Research

Research examined the use of the medicine in some subgroups, such as women with hypertensive disorders. However, data for certain groups remain insufficient. For instance, women with severe pre-existing conditions were often excluded from the main trials. Evidence highlights what is known — and what is still uncertain, and research is ongoing to fully understand long-term patterns and optimal use.

Key Studies & References

1. Australian Public Assessment Report for Carbetocin (TGA)

Common questions about Duratocin (FAQ)

Q: Does this medication make you sleepy or drowsy?

According to official regulatory documents and the results from clinical trials, somnolence (a medical term for drowsiness) and fatigue are listed as commonly reported side effects. Due to these potential effects, it is generally recommended to use caution when performing activities that require full mental alertness until you know how the medication affects you.

---

Q: Can I drink alcohol while taking this medicine?

Regulatory product information states that concurrent use of Duratocin with alcohol is advised against by regulatory product information. This is because combining the two may increase the risk of certain side effects that affect the central nervous system.

---

Q: Is this medication safe to use during pregnancy?

Official regulatory product information addresses the use of Duratocin during pregnancy by providing a risk summary. Regulatory documents state that use may be considered only after weighing the potential benefits against the potential risks to the fetus. Specific clinical advice should come from a healthcare provider.

---

Q: How should I store the medication?

Official product information specifies that Duratocin should be stored at controlled room temperature, away from excessive moisture and heat, as specified in the official storage instructions. Official storage instructions also specify keeping the medication in its original container.

---

Q: Can I take this medication if I have high blood pressure?

The Warnings and Precautions section in the regulatory label addresses the use of Duratocin in patients with pre-existing cardiovascular conditions. The regulatory label indicates that careful consideration and monitoring may be necessary when Duratocin is used in patients with such conditions, including high blood pressure.

---

Q: Can children 2 years old use it?

The regulatory label indicates that Duratocin is approved for use in pediatric patients starting from 6 years of age. Official product information states that the safety and effectiveness of the medication have not been established in children under the age of 6 years.

---

Q: Is this medication safe for long-term use?

Clinical studies have evaluated Duratocin for use within a specific, approved duration of treatment. The official labeling specifies the maximum duration of therapy that was evaluated in clinical trials.

How to Store and Dispose of Duratocin

Storage and disposal of Duratocin (carbetocin injection) must adhere strictly to official regulatory requirements, as the product is a sterile solution administered in a clinical setting.

Official Storage and Handling

Requirement	Instruction
Temperature	Store below 30 C (86 F). Do not freeze.
Protection	Vials must be kept in the original container and in the outer carton to protect from light.
Stability	The product is a single-use vial. Once opened, the solution should be used immediately and the unused portion must be discarded.
Inspection	The solution must be clear and colourless before use.
Child Safety	The medicine is not intended for use in children.

Disposal Instructions

Any unused or expired product is the responsibility of the administering facility. Unused medicine will be safely disposed of by the hospital or pharmacy in accordance with local pharmaceutical waste requirements.